Sodium Oxybate
Phase 2/3Completed 0 watching 0 views this week📈 Rising
62
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Binge Eating Disorder
Conditions
Binge Eating Disorder
Trial Timeline
Aug 1, 2007 → Apr 1, 2011
NCT ID
NCT00514995About Sodium Oxybate
Sodium Oxybate is a phase 2/3 stage product being developed by Jazz Pharmaceuticals for Binge Eating Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00514995. Target conditions include Binge Eating Disorder.
Hype Score Breakdown
Clinical
22
Activity
15
Company
7
Novelty
7
Community
8
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04006925 | Approved | Completed |
| NCT00931164 | Phase 1/2 | Completed |
| NCT00594256 | Phase 2 | Completed |
| NCT00514995 | Phase 2/3 | Completed |
| NCT00506974 | Approved | Completed |
| NCT00641186 | Phase 2 | Completed |
Competing Products
11 competing products in Binge Eating Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine + Placebo | Eli Lilly | Approved | 85 |
| Zonegran + sugar pill | Eisai | Phase 3 | 77 |
| Dasotraline + Placebo | Sumitomo Pharma | Phase 2/3 | 65 |
| dasotraline 4mg + dasotraline 6mg + Placebo | Sumitomo Pharma | Phase 3 | 77 |
| Dasotraline | Sumitomo Pharma | Phase 3 | 77 |
| Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + Placebo | Novo Nordisk | Phase 3 | 76 |
| Solriamfetol + Placebo | Jazz Pharmaceuticals | Approved | 82 |
| Solriamfetol 75mg, 150 mg, or 300 mg | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| RDC-0313 (ALKS 33) + Placebo | Alkermes | Phase 2 | 49 |
| ACT-539313 + Placebo | Idorsia | Phase 2 | 47 |